Response to the comments received on article “Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial” by Udwadia et al

Detalles Bibliográficos
Autores principales: Udwadia, Zarir F., Barkate, Hanmant, Patil, Saiprasad, Rangwala, Shabbir, Wu, Wen, Caracta, Cynthia F., Tandon, Monika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: GLENMARK PHARMACEUTICALS LIMITED. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8012082/
https://www.ncbi.nlm.nih.gov/pubmed/33601032
http://dx.doi.org/10.1016/j.ijid.2021.02.028
_version_ 1783673312616906752
author Udwadia, Zarir F.
Barkate, Hanmant
Patil, Saiprasad
Rangwala, Shabbir
Wu, Wen
Caracta, Cynthia F.
Tandon, Monika
author_facet Udwadia, Zarir F.
Barkate, Hanmant
Patil, Saiprasad
Rangwala, Shabbir
Wu, Wen
Caracta, Cynthia F.
Tandon, Monika
author_sort Udwadia, Zarir F.
collection PubMed
description
format Online
Article
Text
id pubmed-8012082
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher GLENMARK PHARMACEUTICALS LIMITED. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
record_format MEDLINE/PubMed
spelling pubmed-80120822021-04-01 Response to the comments received on article “Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial” by Udwadia et al Udwadia, Zarir F. Barkate, Hanmant Patil, Saiprasad Rangwala, Shabbir Wu, Wen Caracta, Cynthia F. Tandon, Monika Int J Infect Dis Letter to the Editor GLENMARK PHARMACEUTICALS LIMITED. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021-04 2021-02-15 /pmc/articles/PMC8012082/ /pubmed/33601032 http://dx.doi.org/10.1016/j.ijid.2021.02.028 Text en © 2021 GLENMARK PHARMACEUTICALS LIMITED Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Letter to the Editor
Udwadia, Zarir F.
Barkate, Hanmant
Patil, Saiprasad
Rangwala, Shabbir
Wu, Wen
Caracta, Cynthia F.
Tandon, Monika
Response to the comments received on article “Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial” by Udwadia et al
title Response to the comments received on article “Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial” by Udwadia et al
title_full Response to the comments received on article “Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial” by Udwadia et al
title_fullStr Response to the comments received on article “Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial” by Udwadia et al
title_full_unstemmed Response to the comments received on article “Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial” by Udwadia et al
title_short Response to the comments received on article “Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial” by Udwadia et al
title_sort response to the comments received on article “efficacy and safety of favipiravir, an oral rna-dependent rna polymerase inhibitor, in mild-to-moderate covid-19: a randomized, comparative, open-label, multicenter, phase 3 clinical trial” by udwadia et al
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8012082/
https://www.ncbi.nlm.nih.gov/pubmed/33601032
http://dx.doi.org/10.1016/j.ijid.2021.02.028
work_keys_str_mv AT udwadiazarirf responsetothecommentsreceivedonarticleefficacyandsafetyoffavipiraviranoralrnadependentrnapolymeraseinhibitorinmildtomoderatecovid19arandomizedcomparativeopenlabelmulticenterphase3clinicaltrialbyudwadiaetal
AT barkatehanmant responsetothecommentsreceivedonarticleefficacyandsafetyoffavipiraviranoralrnadependentrnapolymeraseinhibitorinmildtomoderatecovid19arandomizedcomparativeopenlabelmulticenterphase3clinicaltrialbyudwadiaetal
AT patilsaiprasad responsetothecommentsreceivedonarticleefficacyandsafetyoffavipiraviranoralrnadependentrnapolymeraseinhibitorinmildtomoderatecovid19arandomizedcomparativeopenlabelmulticenterphase3clinicaltrialbyudwadiaetal
AT rangwalashabbir responsetothecommentsreceivedonarticleefficacyandsafetyoffavipiraviranoralrnadependentrnapolymeraseinhibitorinmildtomoderatecovid19arandomizedcomparativeopenlabelmulticenterphase3clinicaltrialbyudwadiaetal
AT wuwen responsetothecommentsreceivedonarticleefficacyandsafetyoffavipiraviranoralrnadependentrnapolymeraseinhibitorinmildtomoderatecovid19arandomizedcomparativeopenlabelmulticenterphase3clinicaltrialbyudwadiaetal
AT caractacynthiaf responsetothecommentsreceivedonarticleefficacyandsafetyoffavipiraviranoralrnadependentrnapolymeraseinhibitorinmildtomoderatecovid19arandomizedcomparativeopenlabelmulticenterphase3clinicaltrialbyudwadiaetal
AT tandonmonika responsetothecommentsreceivedonarticleefficacyandsafetyoffavipiraviranoralrnadependentrnapolymeraseinhibitorinmildtomoderatecovid19arandomizedcomparativeopenlabelmulticenterphase3clinicaltrialbyudwadiaetal

Ejemplares similares